GlaxoSmithKline. OJJAARA (momelotinib): US prescribing information 2023. https://ojjaara.com/. Accessed 19 Sep 2023.

Ikeda K, Ueda K. Gaining MOMENTUM against anaemic myelofibrosis. Lancet. 2023;401(10373):248–9.

Article  PubMed  Google Scholar 

Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141(16):1954–70.

Article  CAS  PubMed  Google Scholar 

Bassiony S, Harrison CN, McLornan DP. Evaluating the safety, efficacy, and therapeutic potential of momelotinib in the treatment of intermediate/high-risk myelofibrosis: evidence to date. Ther Clin Risk Manag. 2020;16:889–901.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verstovsek S, Chen CC, Egyed M, et al. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol. 2021;17(12):1449–58.

Article  CAS  PubMed  Google Scholar 

Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022;15(1):7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Passamonti F, Harrison CN, Mesa RA, et al. Anemia in myelofibrosis: current and emerging treatment options. Crit Rev Oncol Hematol. 2022;180: 103862.

Article  PubMed  Google Scholar 

GlaxoSmithKline. Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia [media release]. 15 Sep 2023. https://www.gsk.com/.

European Medicines Agency. CHMP summary of positive opinion for Omjjara (momelotinib). 2023. https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-omjjara_en.pdf. Accessed 14 Oct 2023.

GlaxoSmithKline. GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator [media release]. 11 Sep 2023. https://www.gsk.com/.

GlaxoSmithKline. GSK completes acquisition of Sierra Oncology [media release]. 1 Jul 2022. http://www.gsk.com.

Sierra Oncology Inc. Sierra Oncology acquires momelotinib, an investigational Janus kinase (JAK) 1/2 and activin receptor type 1 (ACVR1) inhibitor for myelofibrosis, from Gilead Sciences [media release]. 22 Aug 2018. https://www.prnewswire.com/news-releases/sierra-oncology-acquires-momelotinib-an-investigational-janus-kinase-jak-12-and-activin-receptor-type-1-acvr1-inhibitor-for-myelofibrosis-from-gilead-sciences-300700644.html.

Gilead Sciences Inc. Gilead Sciences completes acquisition of YM BioSciences [media release]. 8 Feb 2013. https://www.gilead.com.

YM BioSciences Inc. YM BioSciences completes merger with Cytopia [media release]. 1 Feb 2010. https://www.prnewswire.com/news-releases/ym-biosciences-completes-merger-with-cytopia-83235132.html.

Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129(13):1823–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng J, Xin Y, Zhang J, et al. Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018;46(3):237–47.

Article  CAS  PubMed  Google Scholar 

Oh ST, Talpaz M, Gerds AT, et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020;4(18):4282–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6):1322–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xin Y, Shao L, Maltzman J, et al. The relative bioavailability, food effect, and drug interaction with omeprazole of momelotinib tablet formulation in healthy subjects. Clin Pharmacol Drug Dev. 2018;7(3):277–86.

Article  CAS  PubMed  Google Scholar 

Xin Y, Kawashima J, Weng W, et al. Pharmacokinetics and safety of momelotinib in subjects with hepatic or renal impairment. J Clin Pharmacol. 2018;58(4):522–32.

Article  CAS  PubMed  Google Scholar 

Verstovsek S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401(10373):269–80.

Article  CAS  PubMed  Google Scholar 

Gerds AT, Verstovsek S, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol. 2023;10(9):e735–46.

Article  CAS  PubMed  Google Scholar 

Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gupta V, Oh S, Devos T, et al. Clinical outcomes with momelotinib vs ruxolitinib in patients with myelofibrosis and anemia: subgroup analysis of SIMPLIFY-1 [abstract no. MPN-551]. Clin Lymphoma Myeloma Leuk. 2023;23(Suppl 1):S402–3.

Article  Google Scholar 

Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73–81.

Article  PubMed  Google Scholar